Role of Blood Lactate Level in Prediction of Outcome of Cirrhotic Patients at The Intensive Care Unit

Launched by ASSIUT UNIVERSITY · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how blood lactate levels can help predict the chances of survival for patients with severe liver cirrhosis who are in the Intensive Care Unit (ICU). Researchers want to understand how well these blood tests, along with other health indicators, can forecast both in-hospital and 28-day mortality rates for these patients. This information could help doctors make better decisions about treatment for critically ill cirrhotic patients.

To be eligible for the trial, participants must be at least 18 years old and have been admitted to the ICU for more than 24 hours due to liver cirrhosis. However, individuals who are admitted for liver transplantation or those whose blood lactate information is not available after 24 hours will not be included. If you or a loved one qualifies and participates in this study, you can expect monitoring of blood tests and other health measures to help researchers gather important data about the condition and treatment outcomes. The trial is currently not recruiting participants, so there will be more updates in the future about when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Cirrhotic patients who are at least 18 years old at their first ICU admission in Al-Rajhy University Hospital (according to the established admission policy) and stay more than 24 h will be included.
• Exclusion Criteria:
• • 1) Patients admitted for liver transplantation.
• • 2) Patients whose blood lactate data is lost at 24 hours from ICU admission.
• • 3) Patients taking drugs that increase level of serum lactate as metformin , acetaminophen, linezolid, epinephrine, beta2 agonists, propofol, nucleoside reverse transcriptase inhibitors (NRTIs) as lamivudine and abacavir , and theophylline